Please ensure Javascript is enabled for purposes of website accessibility

Why Atara Biotherapeutics Stock Is Imploding Today

By George Budwell – Updated May 9, 2019 at 3:26PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors are growing impatient with this clinical-stage biotech.

What happened

Shares of Atara Biotherapeutics (ATRA 1.85%), a leader in the off-the-shelf adoptive cell therapy space, lost as much as 22% of their value in early morning trading today. What event triggered this hefty sell-off?

Ahead of the opening bell, Atara dropped its first-quarter earnings report. The issue that seems to have drawn the ire of investors is the news that enrollment in the company's dual late-stage trials for tab-cel -- an off-the-shelf cell therapy for patients with Epstein-Barr virus associated post-transplant lymphoproliferative disease -- is progressing slower than the company originally anticipated. As of 2:19 p.m. EDT on Thursday, Atara's shares were still down by a lofty 19.1% in the wake of this first-quarter earnings report.

Green chalkboard chart showing a positive trend abruptly turn negative.

Image source: Getty Images.

So what

This clinical update shouldn't be taken as a surefire sign that tab-cel's late-stage trials are going off the rails by any stretch of the imagination. Fairly or unfairly, though, investors do tend to keep close watch on enrollment rates for experimental therapies for a variety of reasons.

Not only does enrollment rate help to clue in investors as to when a study might yield top-line results, but it can also provide valuable insight into the enthusiasm among patients and clinicians toward a particular therapy. That said, investors definitely shouldn't read too deeply into tab-cel's slow enrollment figures. It could boil down to nothing more than a logistical issue. 

Now what

After Atara's CEO Isaac Ciechanover abruptly decided to step down earlier this year, the company's shareholders have been on edge. So it's not surprising that investors are treating this enrollment news as a seriously bad omen.

The key issue for investors to keep in mind, though, is that Atara's underlying value proposition hasn't changed at all since the start of the year. All that matters is tab-cel's forthcoming data readouts. The rest is simply fodder for day traders and short-sellers.

George Budwell owns shares of Atara Biotherapeutics. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Atara Biotherapeutics, Inc. Stock Quote
Atara Biotherapeutics, Inc.
$3.85 (1.85%) $0.07

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.